Clinical Trials Browser

Phase 2 × Prostatic Neoplasms × STA 9090 × Clear all

NCT01270880 2018-09-18

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Phase 2 Completed

18 enrolled 8 charts

Prostatic Neoplasms